Skip to content

Study · Animal study (in vivo) · rat · 2015

4 results

Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats.

Vinodraj K, Nagendra Nayak IM, Rao JV, Mathai P, Chandralekha N, Nitasha B, Rajesh D, Chethan TK

Indian journal of pharmacology1 Mar 2015Cited by 7 (Europe PMC)

PMID25878378 (opens in a new tab)PMCIDPMC4386127 (opens in a new tab)DOI10.4103/0253-7613.153426 (opens in a new tab)PepBankPUB-25878378
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given dexamethasone, liraglutide significantly reduced hepatomegaly compared with dexamethasone alone (P < 0.01).

    In plain wordsIn rats given dexamethasone, liraglutide reduced liver enlargement compared with dexamethasone alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseHepatomegaly (liver weight and volume)
    Study

    ratn: not reported in source

    Albino rats with dexamethasone-induced hepatic steatosis, dyslipidemia and hyperglycemia
    Comparator
    Dexamethasone alone
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.8 mg/kg · subcutaneous · 6 days before and 6 days during dexamethasone administrationAs given in this study (rat).

    Source sentences

    Summary
    Both pioglitazone and liraglutide significantly reduced hepatomegaly, dyslipidemia and hyperglycemia (P < 0.01).
    2 context sentences
    Summary · context
    Second group received liraglutide 1.8 mg/kg subcutaneously 6 days before dexamethasone and 6 days during dexamethasone administration.
    Summary · context
    First group received dexamethasone alone in a dose of 8 mg/kg intraperitoneally for 6 days to induce metabolic changes and considered as dexamethasone control.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given dexamethasone, liraglutide significantly reduced dyslipidemia compared with dexamethasone alone (P < 0.01).

    In plain wordsIn rats given dexamethasone, liraglutide reduced raised blood fats compared with dexamethasone alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseDyslipidemia (lipid profile)
    Study

    ratn: not reported in source

    Albino rats with dexamethasone-induced hepatic steatosis, dyslipidemia and hyperglycemia
    Comparator
    Dexamethasone alone
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg/kg · subcutaneous · 6 days before and 6 days during dexamethasone administrationAs given in this study (rat).

    Source sentences

    Summary
    Both pioglitazone and liraglutide significantly reduced hepatomegaly, dyslipidemia and hyperglycemia (P < 0.01).
    2 context sentences
    Summary · context
    Second group received liraglutide 1.8 mg/kg subcutaneously 6 days before dexamethasone and 6 days during dexamethasone administration.
    Summary · context
    First group received dexamethasone alone in a dose of 8 mg/kg intraperitoneally for 6 days to induce metabolic changes and considered as dexamethasone control.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given dexamethasone, liraglutide significantly reduced hyperglycemia compared with dexamethasone alone (P < 0.01).

    In plain wordsIn rats given dexamethasone, liraglutide reduced high blood sugar compared with dexamethasone alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseHyperglycemia (fasting blood sugar)
    Study

    ratn: not reported in source

    Albino rats with dexamethasone-induced hepatic steatosis, dyslipidemia and hyperglycemia
    Comparator
    Dexamethasone alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/kg · subcutaneous · 6 days before and 6 days during dexamethasone administrationAs given in this study (rat).

    Source sentences

    Summary
    Both pioglitazone and liraglutide significantly reduced hepatomegaly, dyslipidemia and hyperglycemia (P < 0.01).
    2 context sentences
    Summary · context
    Second group received liraglutide 1.8 mg/kg subcutaneously 6 days before dexamethasone and 6 days during dexamethasone administration.
    Summary · context
    First group received dexamethasone alone in a dose of 8 mg/kg intraperitoneally for 6 days to induce metabolic changes and considered as dexamethasone control.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats given dexamethasone, the reduction of blood sugar after a glucose load was significantly larger with pioglitazone than with liraglutide (P < 0.01).

    In plain wordsIn rats given dexamethasone, pioglitazone lowered blood sugar after a glucose load more than liraglutide did.

    Peptide
    Liraglutide
    Outcome
    IncreaseBlood sugar 2 h after glucose load, liraglutide vs pioglitazone
    Study

    ratn: not reported in source

    Albino rats with dexamethasone-induced hepatic steatosis, dyslipidemia and hyperglycemia
    Comparator
    Pioglitazone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/kg · subcutaneous · 6 days before and 6 days during dexamethasone administrationAs given in this study (rat).

    Source sentences

    Summary
    Reduction of blood sugar levels after glucose load was significant with pioglitazone when compared with liraglutide (P < 0.01).
    2 context sentences
    Summary · context
    Second group received liraglutide 1.8 mg/kg subcutaneously 6 days before dexamethasone and 6 days during dexamethasone administration.
    Summary · context
    First group received dexamethasone alone in a dose of 8 mg/kg intraperitoneally for 6 days to induce metabolic changes and considered as dexamethasone control.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.